Low frequency of ras gene mutations in neuroblastomas, pheochromocytomas, and medullary thyroid cancers - PubMed (original) (raw)
. 1991 Mar 15;51(6):1596-9.
Affiliations
- PMID: 1998949
Low frequency of ras gene mutations in neuroblastomas, pheochromocytomas, and medullary thyroid cancers
J F Moley et al. Cancer Res. 1991.
Abstract
Little is known about the prevalence and significance of ras gene activation in neural crest tumors such as neuroblastomas, pheochromocytomas, and medullary thyroid cancers (MTCs). Therefore, we analyzed DNA from 10 human neuroblastoma cell lines and 10 primary human pheochromocytomas for activating mutations in N-ras, H-ras, and K-ras. We also studied DNA from 24 primary neuroblastomas and 10 MTCs for N-ras mutations. ras genes were analyzed by direct sequencing of specific DNA fragments amplified by the polymerase chain reaction. With the exception of the SK-N-SH cell line, the examined ras gene sequences were normal in all the neuroblastomas, pheochromocytomas, and MTCs tested. A single point mutation was identified at codon 59 (GCT(ala)----ACT(thr)) in one N-ras allele in an SK-N-SH subline. Interestingly, this mutation is different from the activating codon 61 mutation which resulted in the initial identification of N-ras from SK-N-SH DNA. Therefore, we analyzed the sequences of earlier passages and sublines of the SK-N-SH cell line, but mutations at codon 59 or 61 were not detected, suggesting that neither mutation was present in the primary tumor. Our results indicate that N-ras mutations may occur spontaneously during in vitro passage of cell lines but rarely, if ever, occur in primary neuroblastomas, pheochromocytomas, and MTCs. In addition, we have not found H-ras or K-ras mutations in any neuroblastoma cell line or primary pheochromocytoma.
Similar articles
- Prevalence of RAS point mutations in papillary thyroid carcinoma; a novel mutation at codon 31 of K-RAS.
Cyniak-Magierska A, Brzeziańska E, Januszkiewicz-Caulier J, Jarzab B, Lewiński A. Cyniak-Magierska A, et al. Exp Clin Endocrinol Diabetes. 2007 Oct;115(9):594-9. doi: 10.1055/s-2007-981670. Exp Clin Endocrinol Diabetes. 2007. PMID: 17943694 - Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma.
Kong XT, Choi SH, Inoue A, Xu F, Chen T, Takita J, Yokota J, Bessho F, Yanagisawa M, Hanada R, Yamamoto K, Hayashi Y. Kong XT, et al. Cancer Res. 1997 Sep 1;57(17):3772-8. Cancer Res. 1997. PMID: 9288786 - Activated N-ras oncogenes in human neuroblastoma.
Ireland CM. Ireland CM. Cancer Res. 1989 Oct 15;49(20):5530-3. Cancer Res. 1989. PMID: 2676145 - K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.
Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos JL. Hruban RH, et al. Am J Pathol. 1993 Aug;143(2):545-54. Am J Pathol. 1993. PMID: 8342602 Free PMC article. Review. - Biology of tumors of the peripheral nervous system.
Brodeur GM, Moley JF. Brodeur GM, et al. Cancer Metastasis Rev. 1991 Dec;10(4):321-33. doi: 10.1007/BF00554794. Cancer Metastasis Rev. 1991. PMID: 1786633 Review.
Cited by
- Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.
Shukla N, Ameur N, Yilmaz I, Nafa K, Lau CY, Marchetti A, Borsu L, Barr FG, Ladanyi M. Shukla N, et al. Clin Cancer Res. 2012 Feb 1;18(3):748-57. doi: 10.1158/1078-0432.CCR-11-2056. Epub 2011 Dec 5. Clin Cancer Res. 2012. PMID: 22142829 Free PMC article. - A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma.
Mlakar V, Morel E, Mlakar SJ, Ansari M, Gumy-Pause F. Mlakar V, et al. J Exp Clin Cancer Res. 2021 Jun 8;40(1):189. doi: 10.1186/s13046-021-01967-x. J Exp Clin Cancer Res. 2021. PMID: 34103089 Free PMC article. Review. - Malignant fibrous histiocytomas and H-ras-1 oncogene point mutations.
Rieske P, Bartkowiak J, Szadowska A, Debiec-Rychter M. Rieske P, et al. Mol Pathol. 1999 Apr;52(2):64-7. doi: 10.1136/mp.52.2.64. Mol Pathol. 1999. PMID: 10474683 Free PMC article. - LGR5 regulates pro-survival MEK/ERK and proliferative Wnt/β-catenin signalling in neuroblastoma.
Vieira GC, Chockalingam S, Melegh Z, Greenhough A, Malik S, Szemes M, Park JH, Kaidi A, Zhou L, Catchpoole D, Morgan R, Bates DO, Gabb PD, Malik K. Vieira GC, et al. Oncotarget. 2015 Nov 24;6(37):40053-67. doi: 10.18632/oncotarget.5548. Oncotarget. 2015. PMID: 26517508 Free PMC article. - Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes.
Kratz CP, Rapisuwon S, Reed H, Hasle H, Rosenberg PS. Kratz CP, et al. Am J Med Genet C Semin Med Genet. 2011 May 15;157C(2):83-9. doi: 10.1002/ajmg.c.30300. Epub 2011 Apr 15. Am J Med Genet C Semin Med Genet. 2011. PMID: 21500339 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous